Suchergebnisse - "Cubillo, Antonio"

PubPharm (74)

31

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

enthalten in: Cancer medicine | 2018

von Fogelman, D. | Cubillo, A. | García-Alfonso, P. | +12

32

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

enthalten in: International journal of cancer | 2018

von Van Cutsem, E. | Hidalgo, M. | Canon, J. | +11

33

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Toledo, R. | Garralda, E. | Mitsi, M. | +20

34

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses : A Phase 2 Randomized Clinical Trial

enthalten in: JAMA oncology | 2018

von Montagut, C. | Argilés, G. | Ciardiello, F. | +29

ErratumIn: JAMA Oncol. 2019 May 1;5(5):745. - PMID 31070664

35

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

enthalten in: Neuroendocrinology | 2018

von Raymond, E. | Kulke, M. | Qin, S. | +27

36

A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma

enthalten in: Surgical oncology | 2017

von Ielpo, B. | Caruso, R. | Duran, H. | +11

37

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer : A Review

enthalten in: Current pharmacogenomics and personalized medicine | 2017

von Rodriguez-Pascual, J. | Cubillo, A.

38

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab

enthalten in: Oncotarget | 2017

von Toledo, R. | Cubillo, A. | Vega, E. | +11

39

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy : a Q-TWiST analysis

enthalten in: British journal of cancer | 2017

von Pelzer, U. | Blanc, J. | Melisi, D. | +11

40

Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Paz-Ares, L. | Forster, M. | Boni, V. | +9